Gene Network Sciences Announces Brain Cancer Collaboration With M.D. Anderson
Posted on: Tuesday, 14 April 2009, 09:17 CDT
The rich glioblastoma dataset produced by M.D. Anderson researchers, which includes genetic, genomic, and clinical endpoint data ("3-D Data"), will be analyzed using GNS's supercomputer-driven REFS(TM) (Reverse Engineering and Forward Simulation) software platform. These analyses are expected to generate models that enable the discovery of key genes, proteins and other molecular entities that together, as a network, causally drive glioblastoma disease progression, disease recurrence, and survival. The results from these projects will include the identification of new combination drug targets for disease and the development of diagnostics to determine appropriate individual patient treatments.
"There continues to be an urgent need for a more efficient translation of research into improved treatments for glioblastoma patients," said Dr.
The parties plan to transform this coherent clinical 3-D Data into computer models which link genetic alterations to changes in gene expression to progression-free patient survival times. This computer model, developed by using the REFS(TM) platform, is expected to unravel the complex genetic circuitry underlying glioblastoma and reveal novel drug targets and markers of response. These targets and markers may be used to identify the optimal single or combination drug therapy for a given patient's genetic alteration profile. The parties will utilize M.D. Anderson's clinical expertise to validate the discoveries and will work with strategic partners to make drugs and diagnostics stemming from these discoveries available to patients.
"GNS is excited to be working with one of the world's foremost research and clinical care institutions to rapidly translate lab bench research into bedside results," said
About Gene Network Sciences
Gene Network Sciences (http://www.gnsbiotech.com/) is a leader in biosimulation with its ability to derive molecular mechanisms of drugs and diseases directly from molecular profiling and clinical data. Based in
About M.D. Anderson
The
SOURCE Gene Network Sciences, Inc
Source: PR Newswire
Related Articles
- Spectrum Pharmaceuticals Presents Data on Lucanthone, a Novel Anticancer Drug, at the Meeting of the American Association of Cancer Research
- Response Genetics, Inc. Announced Results of Pre-Clinical Studies on Gene Expression at the American Association for Cancer Research 2008 Annual Meeting
- Cytokinetics Announces Non-Clinical and Clinical Data Relating to GSK-923295 to Be Presented at the 2008 American Association of Cancer Research Annual Meeting
- Gene Network Sciences Announces Cancer Research Collaboration With Moffitt Cancer Center
- Immunicon Corporation to Present at 2006 Meeting of the American Association for Cancer Research
- Sunesis Pharmaceuticals to Present Data on Clinical-Stage Product Candidates at the Annual Meeting of the American Association for Cancer Research
- Cancer Research Institute Starts First Phase I Clinical Trial; New Drug Targets Prostate Cancer Cells
- AVI BioPharma Presents Positive Results With NEUGENE Antisense Drugs At the American Association for Cancer Research Meeting
- OSI Pharmaceuticals Summarizes Pre-Clinical Data From Its Research & Development Program Presented at the 96th Annual Meeting of the American Association for Cancer Research
- Sunesis Presents Data on Novel Anti-Cancer Drug at American Association of Cancer Research Meeting
 |
 |
User Comments (0)
RSS Feeds